2707203-34-5
Chemical Structure
Trelagliptin-13C,d3
Synonym(s): SYR-472-13C,d3
- CAS No.: 2707203-34-5
- Formula:C1713CH17D3FN5O2
- Molecular Weight:361.39
IUPAC Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-(methyl-13C-d3)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
InChIKey: IWYJYHUNXVAVAA-GKOPAMJVSA-N
SMILES: N#CC1=CC=C(F)C=C1CN(C(N2[13C]([2H])([2H])[2H])=O)C(N3C[C@H](N)CCC3)=CC2=O
Biological Activity: Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin[1]. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trelagliptin-13C,d3 | Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trelagliptin (Standard) | ≥98% | Trelagliptin (Standard) is the analytical standard of Trelagliptin. This product is intended for research and analytical applications. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trelagliptin | 99.81% | Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605. [Content Brief]
